Acalabrutinib

Treatment-naive patients with chronic lymphocytic leukemia who received acalabrutinib demonstrated durable responses with no new long-term safety issues, according to long-term phase 2 data presented at ASCO20 Virtual Scientific Program.

ORLANDO — In this video at ASH Annual Meeting and Exposition, Ryan W. Jacobs, MD, discusses the implications of the ELEVATE-TN trial, which showed acalabrutinib alone or in combination with obinutuzumab extended PFS compared with obinutuzumab and chlorambucil among patients with treatment-naive chronic lymphocytic leukemia.

ORLANDO — The combination of acalabrutinib, venetoclax and obinutuzumab demonstrated high rates of complete response and undetectable minimal residual disease in bone marrow among patients with previously untreated chronic lymphocytic leukemia, according to results of a single-arm phase 2 study presented at ASH Annual Meeting and Exposition.

ORLANDO — Acalabrutinib alone and in combination with obinutuzumab improved PFS compared with obinutuzumab and chlorambucil among patients with treatment-naive chronic lymphocytic leukemia, according to results of the randomized phase 3 ELEVATE-TN study presented at ASH Annual Meeting and Exposition.

Joshua Brody, MD, director of the lymphoma immunotherapy program, Icahn School of Medicine at Mount Sinai, and HemOnc Today Next Gen Innovator, discussed some highlights to look forward to at this year’s ASH annual meeting, including novel therapeutics and how the data will impact clinical practice. 

The FDA today approved acalabrutinib as initial or subsequent therapy for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Healio spoke with Shazia K. Nakhoda, MD, about CLL highlights from recent conferences.

Healio spoke with Shazia K. Nakhoda, MD, about incorporating new therapies into practice.

Healio spoke with Shazia K. Nakhoda, MD, about recent approvals and advancements in the management of CLL.

Healio spoke with Ryan. W. Jacobs, MD, about complications that can arise in patients with CLL.